TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39152361

Group type: EXPERIMENTAL
Intervention: With R septa (n=10, 12.7%)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Without R septa (n=69, 87.3%)
Number of subjects: 79
Study: 39152408

Group type: EXPERIMENTAL
Intervention: Group-based antenatal care (G-ANC)
Number of subjects: 1285
Study: 39152467

Group type: EXPERIMENTAL
Intervention: Personalized rTMS targeting the primary motor cortex of the lower limb (motor priority group)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Personalized rTMS over the left dorsolateral prefrontal cortex (cognitive priority group)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Active comparator: bilateral rTMS of the primary motor cortex of the upper limb
Number of subjects: 60
Study: 39152477

Group type: EXPERIMENTAL
Intervention: Diabetes mellitus (DM) group
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: Combination of DM and coronary microvascular dysfunction (CMD)
Number of subjects: 2212

Group type: EXPERIMENTAL
Intervention: DM and CMD combination
Number of subjects: 2212

Group type: COMPARATOR
Intervention: Non-DM group
Number of subjects: 2212
Study: 39152484

Group type: EXPERIMENTAL
Intervention: Self-directed psychological intervention consisting of six 10-min video modules addressing cognitive, emotional, and interpersonal aspects of infertility-related distress.
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Self-directed psychological intervention
Number of subjects: 21
Study: 39152487

Group type: EXPERIMENTAL
Intervention: SME tool (web-based intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study: 39152983

Group type: EXPERIMENTAL
Intervention: Cordella Pulmonary Artery sensor
Number of subjects: 456
Study: 39152986

Group type: EXPERIMENTAL
Intervention: High-Intensity Care (HIC)
Number of subjects: 1078

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 1078
Study: 39153000

Group type: EXPERIMENTAL
Intervention: Personal Financial Wellness Scale
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Severe financial distress group (n=26)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 126
Study: 39153060

Group type: EXPERIMENTAL
Intervention: Guselkumab treatment (interleukin-23p19 subunit inhibitor)
Number of subjects: 329
Study: 39153127

Group type: EXPERIMENTAL
Intervention: High NOTCH1 mRNA expression in tumors (n=86)
Number of subjects: 1270

Group type: EXPERIMENTAL
Intervention: High NOTCH1 mRNA expression
Number of subjects: 1270
Study: 39153158

Group type: EXPERIMENTAL
Intervention: Trust Based Relational Intervention (TBRI®)
Number of subjects: 0
Study: 39153426

Group type: EXPERIMENTAL
Intervention: Low-fat yogurt (12 oz/day)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Soy pudding control snack
Number of subjects: 39
Study: 39153490

Group type: EXPERIMENTAL
Intervention: PfSPZ Vaccine (3 doses of 9×10^6 sporozoites)
Number of subjects: 290

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 290
Study: 39153491

Group type: EXPERIMENTAL
Intervention: CADe-assisted colonoscopy
Number of subjects: 2032

Group type: COMPARATOR
Intervention: Standard colonoscopy
Number of subjects: 2032
Study: 39153572

Group type: EXPERIMENTAL
Intervention: Oligoasthenospermia (n = 405)
Number of subjects: 1131

Group type: COMPARATOR
Intervention: Normospermia (n = 726)
Number of subjects: 1131
Study: 39153751

Group type: EXPERIMENTAL
Intervention: SQ-LNS only
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Growth charts only
Number of subjects: 2291

Group type: EXPERIMENTAL
Intervention: Growth charts + SQ-LNS
Number of subjects: 2291

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 2291
Study: 39153752

Group type: EXPERIMENTAL
Intervention: MO care (231 patients)
Number of subjects: 422

Group type: COMPARATOR
Intervention: CA care (191 patients)
Number of subjects: 422
Study: 39153754

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention of decision-supported electronic health records and non-physician care coordinator
Number of subjects: 1146
Study: 39153779

Group type: EXPERIMENTAL
Intervention: rfhSP-D (1 mg/kg, 2 mg/kg, or 4 mg/kg)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Routine surfactant replacement therapy
Number of subjects: 24
Study: 39153787

Group type: EXPERIMENTAL
Intervention: Individualised nutritional support
Number of subjects: 445

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 445
Study: 39153792

Group type: EXPERIMENTAL
Intervention: Resistance training + usual care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Aerobic training + usual care
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Exercise groups (Resistance training or Aerobic training) followed by EBS + usual care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 150

Group type: COMPARATOR
Intervention: Usual care during 40-week follow-up
Number of subjects: 150
Study: 39153816

Group type: EXPERIMENTAL
Intervention: High protein group (2.0 g/kg per day)
Number of subjects: 935

Group type: COMPARATOR
Intervention: Standard protein group (1.3 g/kg per day)
Number of subjects: 935
Study: 39153818

Group type: EXPERIMENTAL
Intervention: Emodepside (30 mg total, six 5 mg tablets)
Number of subjects: 293

Group type: COMPARATOR
Intervention: Albendazole (400 mg, one tablet)
Number of subjects: 293

Group type: EXPERIMENTAL
Intervention: Emodepside
Number of subjects: 293

Group type: COMPARATOR
Intervention: Albendazole
Number of subjects: 293
Study: 39153817

Group type: EXPERIMENTAL
Intervention: Hypothermic oxygenated machine perfusion (HOPE)
Number of subjects: 229

Group type: COMPARATOR
Intervention: Static cold storage (SCS)
Number of subjects: 229
Study: 39153911

Group type: EXPERIMENTAL
Intervention: ON-SXB (sodium oxybate) 9 g at week 13
Number of subjects: 212

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 212

Group type: EXPERIMENTAL
Intervention: ON-SXB (sodium oxybate)
Number of subjects: 212
Study: 39153979

Group type: EXPERIMENTAL
Intervention: COVID-ARDS
Number of subjects: 8117

Group type: COMPARATOR
Intervention: CLASSIC-ARDS
Number of subjects: 8117
Study: 39153977

Group type: EXPERIMENTAL
Intervention: Muay Thai (MT) training for 12 weeks, 3 times a week, 60 minutes per session.
Number of subjects: 50

Group type: COMPARATOR
Intervention: Functional training (FT) for 12 weeks, 3 times a week, 60 minutes per session.
Number of subjects: 50
Study: 39154071

Group type: EXPERIMENTAL
Intervention: Multiplex real-time PCR plus conventional microbiological testing
Number of subjects: 242

Group type: COMPARATOR
Intervention: Conventional microbiological testing alone
Number of subjects: 242
Study: 39154085

Group type: EXPERIMENTAL
Intervention: Mechanical Thrombectomy (MT) for ELVO
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Proteomic analysis of 184 proteins from Olink proteomic (92 Cardiometabolic and 92 Inflammation panels)
Number of subjects: 81
Study: 39154169

Group type: EXPERIMENTAL
Intervention: Parenting programme intervention
Number of subjects: 823
Study: 39154191

Group type: EXPERIMENTAL
Intervention: Training to improve COVID-19 infection control best practices
Number of subjects: 136
Study: 39154298

Group type: EXPERIMENTAL
Intervention: Cluster 1 (23% of the patient sample)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Cluster 2 (39% of the patient sample)
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Cluster 3
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Cluster 4 and 5
Number of subjects: 1360

Group type: EXPERIMENTAL
Intervention: Overall patient clusters
Number of subjects: 1360
Study: 39154299

Group type: EXPERIMENTAL
Intervention: Cytokine adsorber CytoSorb (CS)
Number of subjects: 15
Study: 39154305

Group type: EXPERIMENTAL
Intervention: Biofeedback present, maximal intensity
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Biofeedback present, submaximal intensity
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Biofeedback absent, maximal intensity
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Biofeedback absent, submaximal intensity
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Biofeedback present
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Biofeedback absent
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Maximal intensity
Number of subjects: 84

Group type: EXPERIMENTAL
Intervention: Submaximal intensity
Number of subjects: 84
Study: 39154316

Group type: EXPERIMENTAL
Intervention: Ketamine 1 mg/kg bolus
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fentanyl 1 mcg/kg bolus
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Ketamine
Number of subjects: 86

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 86
Study: 39154486

Group type: EXPERIMENTAL
Intervention: Germline pathogenic variants (PV) identified through sequencing of 250 cancer-related genes.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Germline pathogenic variants classified as ESCAT X.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Actionable variants classified as ESCAT I-A/II-A.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Incidental findings of PVs in cancer-predisposition genes.
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Variants of uncertain significance (VUS).
Number of subjects: 288
Study: 39154597

Group type: EXPERIMENTAL
Intervention: mHealth intervention
Number of subjects: 92
Study: 39154808

Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Numeric Rating Scale (NRS)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: VAS and NRS correlation
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Bland-Altman method
Number of subjects: 100
Study: 39154860

Group type: EXPERIMENTAL
Intervention: PDS (10, 40, or 100 mg/ml) with pro re nata refill-exchanges
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: PDS 100 mg/ml with fixed refill-exchanges every 24 weeks (PDS Q24W)
Number of subjects: 555

Group type: EXPERIMENTAL
Intervention: PDS Q24W from day 1
Number of subjects: 555
Study: 39155155

Group type: EXPERIMENTAL
Intervention: Talquetamab
Number of subjects: 0
Study: 39155367

Group type: EXPERIMENTAL
Intervention: Application of HSOG Guidelines on labor management, training on cardiotocography interpretation, and emergency management in vaginal deliveries.
Number of subjects: 20000

Group type: COMPARATOR
Intervention: Initial observation and recording of routine practice (cesarean section, vaginal birth, maternal and perinatal morbidity and mortality).
Number of subjects: 20000

Group type: EXPERIMENTAL
Intervention: Feedback and performance monitoring for participating units during the intervention period.
Number of subjects: 20000
Study: 39155425

Group type: COMPARATOR
Intervention: Non-DTG regimens
Number of subjects: 313

Group type: EXPERIMENTAL
Intervention: DTG regimens
Number of subjects: 313
Study: 39155576

Group type: EXPERIMENTAL
Intervention: Alternative anthropometric measures (waist-to-height ratio)
Number of subjects: 1116

Group type: COMPARATOR
Intervention: Body mass index (BMI)
Number of subjects: 1116
Study: 39155700

Group type: EXPERIMENTAL
Intervention: HRS-1780 (5, 10, 20, 40, 60, and 80 mg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HRS-1780 (10, 20, and 40 mg) once daily for 7 days
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: HRS-1780
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 39155737

Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg every 2 weeks for up to 96 weeks
Number of subjects: 2282
Study: 39155847

Group type: EXPERIMENTAL
Intervention: OSE2101 + Pembrolizumab
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: OSE2101
Number of subjects: 0

Group type: COMPARATOR
Intervention: Supportive care
Number of subjects: 0
Study: 39156216

Group type: EXPERIMENTAL
Intervention: Current shift work (SW)
Number of subjects: 344

Group type: EXPERIMENTAL
Intervention: Former shift work (SW)
Number of subjects: 344

Group type: COMPARATOR
Intervention: Never-shift workers
Number of subjects: 344
Study: 39156699

Group type: EXPERIMENTAL
Intervention: Fully-automated module for radiolabeling; pH of 3.6 and precursor dose of 30 μg were used.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quality control parameters tested in the fully-automated synthesis protocol.
Number of subjects: 0
Study: 39157060

Group type: EXPERIMENTAL
Intervention: Plantarflexor neurostimulation with individualized tuning
Number of subjects: 10
Study: 39157445

Group type: EXPERIMENTAL
Intervention: Deep learning model for aspiration detection using voice analysis
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Deep learning model with learning rate of 3.00e-5 and batch size of 16
Number of subjects: 198

Group type: EXPERIMENTAL
Intervention: Deep learning model with learning rate of 5.00e-5 and batch size of 32
Number of subjects: 198
Study: 39157776

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention (6-weekly 1.5-hour sessions remotely delivered)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Mindfulness intervention
Number of subjects: 31

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 31
Study: 39158071

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in B-cell ALL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in childhood T-cell ALL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in young adult T-cell ALL
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Daratumumab (16 mg/kg IV) plus backbone chemotherapy in T-cell LL
Number of subjects: 46
Study: 39158295

Group type: EXPERIMENTAL
Intervention: Topical terbinafine hydrochloride 10% solution (MOB015B)
Number of subjects: 0
Study: 39158353

Group type: EXPERIMENTAL
Intervention: Implementation of electronic Patient Reported Outcome (ePRO) system
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: ePRO system
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Baseline PROMIS social functioning and grade 2 or more PRO-CTCAE interference of Abdominal Pain, Decreased Appetite, Dizziness and Shortness of Breath
Number of subjects: 26
Study: 39158557

Group type: EXPERIMENTAL
Intervention: HFimpEF (improved ejection fraction)
Number of subjects: 447

Group type: COMPARATOR
Intervention: non-HFimpEF (no improvement)
Number of subjects: 447
Study: 39158569

Group type: EXPERIMENTAL
Intervention: High-cTnI responders
Number of subjects: 59

Group type: COMPARATOR
Intervention: Normal-cTnI responders
Number of subjects: 59
Study: 39158584

Group type: EXPERIMENTAL
Intervention: mRNA-1273 booster dose (10 µg for 6 months-5 years; 25 µg for 6-11 years)
Number of subjects: 2672

Group type: EXPERIMENTAL
Intervention: mRNA-1273 booster dose
Number of subjects: 2672
Study: 39158589

Group type: EXPERIMENTAL
Intervention: Drug-coated balloons (Passeo-18 lux DCBs)
Number of subjects: 876
Study: 39158670

Group type: EXPERIMENTAL
Intervention: Facilitated subcutaneous immunoglobulin (fSCIG) 10%
Number of subjects: 253
Study: 39158706

Group type: EXPERIMENTAL
Intervention: Nurse facilitator intervention
Number of subjects: 23
Study: 39158741

Group type: EXPERIMENTAL
Intervention: KIND challenge intervention (acts of kindness at least once per week for four weeks)
Number of subjects: 4284

Group type: EXPERIMENTAL
Intervention: KIND challenge intervention
Number of subjects: 4284

Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 4284
Study: 39158761

Group type: EXPERIMENTAL
Intervention: Combined subcision with platelet-rich plasma and microneedling
Number of subjects: 36

Group type: COMPARATOR
Intervention: Combined subcision with saline and microneedling
Number of subjects: 36
Study: 39158832

Group type: EXPERIMENTAL
Intervention: Per-oral endoscopic myotomy (POEM)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Achalasia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Functional gastrointestinal disorders (FGIDs)
Number of subjects: 118
Study: 39158833

Group type: EXPERIMENTAL
Intervention: Recombinant porcine factor VIII (rpFVIII) at an initial dose of 200 U/kg, with subsequent doses based on clinical measures; median total dose was 548.4 U/kg (range: 198-1803 U/kg) with a median of 3.0 infusions per patient.
Number of subjects: 5
Study: 39158851

Group type: COMPARATOR
Intervention: Group Mindfulness-Based Intervention (MBI) via videoconference
Number of subjects: 811

Group type: COMPARATOR
Intervention: Self-paced Mindfulness-Based Intervention (MBI)
Number of subjects: 811

Group type: COMPARATOR
Intervention: Group Mindfulness-Based Intervention (MBI)
Number of subjects: 811
Study: 39158893

Group type: EXPERIMENTAL
Intervention: Localized nicardipine release implants (10 implants at 4 mg each) plus standard of care
Number of subjects: 41

Group type: COMPARATOR
Intervention: Aneurysm repair alone plus standard of care
Number of subjects: 41
Study: 39158894

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (1-g bolus followed by 1-g infusion over 8 hours; n=619)
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Placebo (n=626)
Number of subjects: 1384

Group type: EXPERIMENTAL
Intervention: Tranexamic acid
Number of subjects: 1384

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1384
Study: 39158903

Group type: EXPERIMENTAL
Intervention: App platform-facilitated collaborative palliative care intervention
Number of subjects: 0
Study: 39158912

Group type: COMPARATOR
Intervention: Message from clinician (group 2)
Number of subjects: 3051

Group type: EXPERIMENTAL
Intervention: Message from news story and clinician (group 3)
Number of subjects: 3051

Group type: EXPERIMENTAL
Intervention: Message from family member and clinician (group 4)
Number of subjects: 3051
Study: 39158914

Group type: EXPERIMENTAL
Intervention: PRISM intervention
Number of subjects: 172

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 172
Study: 39158916

Group type: EXPERIMENTAL
Intervention: HSK16149 40 mg/d
Number of subjects: 725

Group type: EXPERIMENTAL
Intervention: HSK16149 80 mg/d
Number of subjects: 725

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study: 39158946

Group type: EXPERIMENTAL
Intervention: Standardized serum β2-microglobulin (B2M)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Standardized serum creatinine (Scr)
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Posttransplant B2M levels
Number of subjects: 97
Study: 39158987

Group type: EXPERIMENTAL
Intervention: COVID-19 patients
Number of subjects: 75

Group type: COMPARATOR
Intervention: non-COVID ICU controls
Number of subjects: 75
Study: 39159183

Group type: EXPERIMENTAL
Intervention: Dolutegravir (DTG)-based antiretroviral therapy
Number of subjects: 1920
Study: 39159190

Group type: EXPERIMENTAL
Intervention: Early Occupational Therapy Intervention program (EOTIPS)
Number of subjects: 60
Study: 39159260

Group type: EXPERIMENTAL
Intervention: Opt-IVF
Number of subjects: 115

Group type: COMPARATOR
Intervention: Control
Number of subjects: 115
Study: 39159269

Group type: EXPERIMENTAL
Intervention: STAR Sick Child Job Aid (SCJA) with CRP measurement
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Integrated Community Care Management (iCCM) SCJA (control)
Number of subjects: 1280
Study: 39159398

Group type: EXPERIMENTAL
Intervention: Visitect CD4 test
Number of subjects: 1495
Study: 39159403

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 268

Group type: EXPERIMENTAL
Intervention: Radiotherapy (30 Gy)
Number of subjects: 268
Study: 39159418

Group type: EXPERIMENTAL
Intervention: Capivasertib with fulvestrant
Number of subjects: 708
Study: 39159450

Group type: EXPERIMENTAL
Intervention: Enhanced psychoeducation about cancer-related sexual morbidity
Number of subjects: 320

Group type: COMPARATOR
Intervention: Standard psychoeducation about cancer-related sexual morbidity
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Communication skills training for discussing concerns with health care providers (received)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Communication skills training for discussing concerns with health care providers (not received)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Communication skills training for discussing concerns with a partner (received)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Communication skills training for discussing concerns with a partner (not received)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Intimacy promotion skills training (received)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Intimacy promotion skills training (not received)
Number of subjects: 320
Study: 39159624

Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 39159648

Group type: COMPARATOR
Intervention: Standard nab-paclitaxel-gemcitabine treatment
Number of subjects: 325

Group type: EXPERIMENTAL
Intervention: Alternating nab-paclitaxel-gemcitabine and gemcitabine alone
Number of subjects: 325
Study: 39159822

Group type: EXPERIMENTAL
Intervention: Kinesiophobia group (TSK score ≥ 37)
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Kinesiophobia group
Number of subjects: 140

Group type: COMPARATOR
Intervention: Males
Number of subjects: 140

Group type: COMPARATOR
Intervention: Females
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: Time from injury to surgery
Number of subjects: 140
Study: 39159865

Group type: EXPERIMENTAL
Intervention: Mild glucose intolerance
Number of subjects: 827
Study: 39159997

Group type: EXPERIMENTAL
Intervention: BEL/RTX (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous rituximab 1000 mg at weeks 4 and 6)
Number of subjects: 263

Group type: COMPARATOR
Intervention: BEL/PBO (subcutaneous belimumab 200 mg/week for 52 weeks + intravenous placebo at weeks 4 and 6)
Number of subjects: 263

Group type: EXPERIMENTAL
Intervention: BEL/RTX
Number of subjects: 263

Group type: COMPARATOR
Intervention: BEL/PBO
Number of subjects: 263
Study: 39160081

Group type: EXPERIMENTAL
Intervention: Appendicolith appendicitis without other complications
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Appendicolith appendicitis with complications (appendiceal gangrene, perforation, and/or abscess)
Number of subjects: 78
Study: 39160086

Group type: EXPERIMENTAL
Intervention: Patients with HFpEF
Number of subjects: 40

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 40
Study: 39160092

Group type: EXPERIMENTAL
Intervention: General Anaesthesia (GA)
Number of subjects: 230

Group type: COMPARATOR
Intervention: Non-General Anaesthesia (Non-GA)
Number of subjects: 230